International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus

Abstract

Background Clinical guidelines are essential in implementing and maintaining nationwide stage-specific diagnostic and therapeutic standards. In 2011, the first German expert consensus guideline defined the evidence for diagnosis and treatment of early and locally advanced esophagogastric cancers. Here, we compare this guideline with other national guidelines as well as current literature.Methods The German S3-guideline used an approved development process with de novo literature research, international guideline adaptation, or good clinical practice. Other recent evidence-based national guidelines and current references were compared with German recommendations.

Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

“…Lymphadenectomy was performed according to current guidelines [29] including a D2-lymphadenectomy and a dissection of the lymph nodes of the lower mediastinum in THG and a two-field lymphadenectomy in TAE.…”

Organotypic slice cultures of human gastric and esophagogastric junction cancer

“…Due to their critical prognosis following curative resection (R0), adjuvant treatment is the standard of care in most parts of the world. Western world studies advise perioperative chemotherapy or chemoradiation , whereas postoperative chemotherapy is the standard of care in East Asia . The preferred chemotherapy regimens are based on fluoropyrimidines and platinum compounds which may be combined with epirubicin or docetaxel .…”

“…Introduction chemoradiation [2][3][4][5], whereas postoperative chemotherapy is the standard of care in East Asia [6][7][8]. The preferred chemotherapy regimens are based on fluoropyrimidines and platinum compounds which may be combined with epirubicin or docetaxel [1,8].…”

Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer

“…It represents the sixth most common cause of cancer-related deaths worldwide (1,2). Due to advances in surgical techniques and multi-modality treatments, the prognosis of non-metastatic esophageal cancer has slowly improved over the past decades (3,4). However, the overall 5-year survival probability is still poor and needs to be considerably improved (5).…”